Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

Robert L. Ferris, MD, PhD, highlights groundbreaking advancements presented at the recent World Congress on Lung Cancer held ...

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear Cell renal cell carcinoma treatment.

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Anil Parwani, MD, PhD, discusses how he sees artificial intelligence technology contributing to personalized medicine and ...

The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib ...

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing ...

The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...

During a Case-Based Roundtable® event, Ursa Brown-Glaberman, MD, discussed options for the treatment of patients with ...

In an interview with Targeted Oncology, Omar Nadeem, MD, discussed the first results from the Immuno-PRISM study in patients ...